natgillin/translations-raw huggingface dataset:
The suitable solvent used in the crystallization step is selected from the group consisting of acetone, methanol, ethanol, propanol, water, ethyl acetate, i-propanol, butanol, i-butanol, s-butanol, t-butanol, hexane, toluene, t-butyl-methyl ether, trichloroethane and the like, and mixtures thereof. 
Prikladna otapala koja se koriste u kristalizacijskom koraku obdabiru se iz skupine koja se sastoji od acetona, metanola, etanola, propanola, vode, etilacetata, i-propanola, butanola, i-butanola, s-butanola, heksana, toluena, f-butil-metil etera i slično, i njihovih smjesa.
optionally converting the product of step (i) to a salt or solvate. 
(3) izbornom prevođenju produkta iz koraka (1) u sol ili solvat.
For example, the disorder is an inflammatory bowel disorder (IBD) such as Crohn's disease. 
Polipeptid ili polinukleotidna sekvenca prema zahtjevu 1 za upotrebu prema zahtjevu 1 naznačen time da je navedeni poremećaj upalni poremećaj crijeva (IBD).
The antibody for use of claim 1, where: the amount of anti-sclerostin antibody administered is from about 1 mg/kg to about 5 mg/kg; 
š Antitijelo za uporabu prema zahtjevu 1, naznačeno time, da je količina Anti-sklerostin antitijela koja se primjenjuje od 1 mg/kg do 3 mg/kg.
Because the tetrabenazine used as the starting material for the reduction reaction is typically a mixture of the RR and SS isomers (i.e. trans -tetrabenazine), the dihydrotetrabenazine formed by the reduction step will have the same trans configuration about the 3- and 11b positions and will take the form of one or more of the known dihydrotetrabenazine isomers shown in Figure 3 above. 
Stoga što se kao polazni materijal za reakciju redukcije koristi tetrabenazin koji je obično smjesa RR 1 SS izomera (to je trans-tetrabenazin), dihidrotetrabenazin formiran redukcijskim korakom imati će istu trans-konfiguraciju na položajima 3- 1 11b- 1 biti će u obliku jednog ili više poznatih izomera dihidrotetrabenazina prikazanih na Slici 5 gore.
is a 5-membered heteroaryl group optionally substituted one or more times with R6; and 
R5 je peteročlana heteroaril-skupina po izboru supstituirana jednom ili više puta s R6; i
The solvent was evaporated under high vacuum and the residue was flash chromatographed on a silica gel column using dichloromethane-methanol (9:1) as eluent. 
Otapalo je upareno pod visokim vakuumom, a ostatak je propušten kroz "flash" kromatografiju na koloni silikagela uz diklorometan - metanol (9:1) kao eluens.
A compound of formula I, or a stereoisomer thereof, 
PATENTNI ZAHTJEVI Spoj formule I, ili njegov stereoizomer, gdje
The method for producing the compound of the formula (1) according to claim 2, using the compound of the formula (8) produced by: 
Postupak dobivanja spoja formule (1) u skladu s patentnim zahtjevom 1, naznačen time što se upotrebljava spoj formule (8), dobiven:
introducing the exhaust gas from the electric power plant to a primary heat exchanger via an exhaust gas supply pipeline to conduct a first indirect heat exchange between the exhaust gas and air from a heat supply system of a vegetables greenhouse and/or a algae culturing house whereby providing heated air for the vegetables greenhouse and/or the algae culturing house; 
uvođenje ispušnog plina iz elektrane u primarni izmjenjivač topline (5) putem cjevovoda za dovod ispušnih plinova (4) za provođenje prve neizravne izmjene topline između ispušnog plina i zraka iz sustava za opskrbu toplinom staklenika za povrće i/ili kuću za uzgoj algi pri čemu se osigurava grijani zrak za staklenik povrća i/ili kuću za uzgoj algi;
"Pharmaceutically-effective amount" means that amount of a compound of the present invention, or of its salt, solvate, hydrate or prodrug thereof that will elicit the biological or medical response of a tissue, system or mammal. 
"Farmaceutski djelotvorna količina" znači da količina spoja prema ovom izumu, ili njegove soli, solvata, hidrata ili predlijeka, postiže biološki ili medicinski odgovor u tkivu, organskom sustavu ili organizmu sisavca.
The antibody, or antigen-binding fragment thereof, of Claim 4, wherein the LCVR is the polypeptide of SEQ ID NO: 9, and the HCVR is the polypeptide of SEQ ID NO: 11. 
Protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 4, naznačeno time što LCVR je polipeptid sa slijedom SEQ ID NO: 9, a HCVR je polipeptid sa slijedom SEQ ID NO: 11.
A glucocorticoid contained in a delayed-release dosage form for use in the treatment of a patient suffering from morning stiffness and pain due to an underlying rheumatic disease and/or osteoarthritis, wherein said treatment is administered once daily for at least two weeks. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu u liječenju bolesnika koji pate od jutarnje ukočenosti i boli zbog reumatske podloge bolesti i/ili osteoartritisa, pri čemu se navedeno liječenje provodi davanjem lijeka jednom dnevno kroz najmanje dva tjedna.
The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is for the improvement of cognition in a subject suffering from Schizophrenia. 
Farmaceutski sastav iz patentnog zahtjeva 3 za uporabu u metodi poboljšanja kognicijekod subjekta koji pati od shizofrenije.
The organic layer is separated from the filtrate and the aqueous layer is extracted with ethyl acetate (2x30 mL). 
Organski sloj izdvoji se iz filtrata, a vodeni sloj ekstrahira etil-acetatom (2 x 30 ml).
Functional foods can be prepared, replacing sucrose by the basic formulation, according to the invention, supplemented with vitamins and minerals to mimic the desired fruit or vegetable composition. 
Zamjenjujući saharozu osnovnom formulacijom prema ovom izumu, kojoj su dodani vitamini i minerali u količinama koje oponašaju sastav željenog voća ili povrća, mogu se pripremiti funkcionalni prehrambeni proizvodi.
Figure 6: Contour plot of the estimated response 
Datum objave europske prijave patenta:
The process according to claim 1, wherein the precipitated calcium carbonate seeds are added to the slurry of Ca(OH)2 in step (c) prior to the carbonation of the slurry of Ca(OH)2, or during the first quarter of the total carbonation time of the carbonation of the slurry of Ca(OH)2. 
Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time da se sjeme taložnog kalcijevog karbonata dodaje u gustu smjesu Ca(OH), u koraku (c) prije karboniziranja guste smjese Ca(OH),, ili tijekom prve četvrtine ukupnog vremena karboniziranja karbonizirane guste smjese Ca(OH),.
wherein RN is a substituted or unsubstituted hydrocarbyl group; wherein RL is a linker moiety, RB is a backbone moiety, and T is a template group which attaches each of the four chelating hydroxypyridinone moieties by their linking groups, and including a 4+ ion of the alpha-emitting 227-thorium radionuclide. 
IV pri čemu Ry je supstituirana ili nesupstituirana hidrokarbilna skupina; pri čemu Rr je vezna skupina, Rg je dio okosnice, i T je skupina predloška koja povezuje svaku od četiri kelatizirajuće hidroksipiridinonske skupine s njihovim vezujućim skupinama, te uključuje 4+ ion alfaemitirajućeg 227-torijevog radionuklida.
Peptide according to claim 8, characterised in that the peptide is coupled to a pharmaceutically acceptable carrier, preferably KLH (Keyhole Limpet Hemocyanin). 
Peptid prema zahtjevu 10, naznačen time, da se peptid spaja na farmaceutski prihvatljivi nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
The compound of any one of claims 7 to 8, wherein the compound of formula IA is: wherein the compound of formula IA is: or wherein each quinolinyl or isoquinolinyl of IA-4, IA-5, IA-6, IA-7, or IA-8 is optionally substituted with 1, 2, or 3 R5. 
pri čemu je spoj formule IA: ili pri čemu je svaki kinolinil ili izokinolinil IA-4, IA-5, IA-6, IA-7 ili IA-8 po izboru supstituiran sa 1, 2 ili 3 R5.
a DNA-targeting segment comprising a nucleotide sequence that is complementary to a target sequence in a target DNA, and 
segment koji cilja na DNK, te koji obuhvaća nukleotidnu sekvencu koja je komplementarna ciljanoj sekvenci u ciljanoj DNK; i
Use of the compound or a pharmaceutically acceptable salt thereof of claim 1, or 4a-phenyl-2,3,4,4a,5,9b-hexahydro-1H-indeno[1,2-b]pyridine or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for treating Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, intractable depression, attention deficit hyperactivity disorder, migraines, schizophrenia, generalized anxiety disorder, obsessive-compulsive disorder, autism, bulimia, or drug addiction. 
Uporaba spoja ili njegove farmaceutski prihvatljive soli prema zahtjevu I, ili 4a-fenil-2,3,4,4a,5,9b-heksahidro-1H- indeno[1,2-b]piridina ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje Alzheimer-ove bolesti, cerebrovaskularne demencije, Parkinson-ove bolesti, ishemijske apopleksije, bolova, neukrotive depresije, poremećaja hiperaktivnosti s nedostatkom pažnje, migrena, shizofrenije, poremećaja opće anksioznosti, opsesivno-kompulzivnog poremećaja, autizma, bulimije ili ovisnosti o drogama.
A hemihydrate form of the sodium salt of pemirolast for use as a pharmaceutical. 
Hemihidratni oblik natrijeve soli pemirolasta.
The cell of claim 1, wherein said nucleic acid molecule is operatively linked with an expression control sequence. 
Stanica prema zahtjevu 1, naznačena time što je ta molekula nukleinske kiseline opartivno povezana s kontrolnom sekvencom ekspresije.
The transdermal delivery device of claims 1 or 11 wherein the opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmephene, diprenorphine, nalmexone, cyprenorphine, alazocine, oxilorphan, cyclophan, nalorphine, nalbuphine, buprenorphine butorphanol, cyclazocine, pentazocine, levallorphan, pharmaceutically acceptable salts thereof, and mixtures thereof; and preferably is naltrexone or a pharmaceutically acceptable addition salt thereof. 
Sredstvo za transdermalno davanje prema zahtjevima od 1 do 11, naznačeno time da je opioidni antagonist odabran iz skupine koja se sastoji od naltreksona, naloksona, nalmefena, diprenorfina, nalmeksona, ciprenorfina, alazocina, oksilorfana, ciklofana, nalorfina, nalbufina, buprenorfina, butorfanola, ciklazocina, pentazocina, lovalorfana, njihovih farmaceutski prihvatljivih soli, i njihovih smjesa; i poželjno je naltrekson ili njegova farmaceutski prihvatljiva sol.
ring A is a benzene ring, pyridine ring or piperidine ring. 
Prsten A je benzenski prsten, piridinov prsten ili piperidinov prsten.
In other embodiments, the immune response is an autoimmune response, including multiple sclerosis, uveitis, systemic lupus erythematosus and diabetes. 
Antitijelo ili antigen-vežući fragment istog iz Zahtjeva 1, naznačeno time, što se koristi za liječenje poremećaja odabranih iz grupe koja se sastoji od multiple skleroze, sistemskog lupusa eritematozusa i dijabetesa.
However, it is preferable that the chitosan-NAC polymer in the formulation of the present invention has a content of free thiol groups in an amount from about 80 umol/g polymer to 280 umol/g polymer; preferably with a range of free thiol groups of about 105 umol/g polymer to 250 umol/g polymer, more preferably of from 110 umol/g polymer to 250 umol/g polymer and most preferably of from preferably 140 to 250 umol/g polymer. 
Oftalmološka otopina prema bilo kojem od prethodnih zahtjeva, naznačena time da N-(N-acetilcisteinil-)kitozan ima sadržaj slobodnih tiol grupa u količini od 105 umol/g polimera do 250 umol/g polimera, poželjno od 110 umol/g polimera do 250 umol/g polimera, najpoželjnije od poželjno 140 do 250 umol/g polimera.
The soft chewable veterinary composition of claim 6, wherein the solvent is a liquid polyethylene glycol or a caprylic/capric triglyceride, or a combination thereof. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 6, naznačen time, da otapalo je tekući polietilenglikol ili kaprilični/kaprički triglicerid, ili njihova kombinacija.
the costimulatory 4-1BB signalling region comprises the amino acid sequence of SEQ ID NO: 23; 
(i) - kostimulatorno signalno područje 4-1 BB sadrži aminokiselinsku sekvencu naznačenu u SEQ ID NO: 23;
An antigen binding protein according to claim 1 part (i)(b), wherein said antigen binding protein has a Koff rate of ≤ 5x10-6 1/s. 
Protein koji veže antigen u skladu s patentnim zahtjevom 1 dio (i)(b), pri čemu navedeni protein koji veže antigen ima Koff udio ≤5x10-6 1/s.
The equipment (10**), as claimed in claim 3, characterized in that said reversible fixing means comprise two series of through holes, a plurality of bolts and a plurality of nuts. 
Uređaj (10%) u skladu s patentnim zahtjevom 3, naznačen time, da navedena reverzibilna sredstva za učvršćivanje sadržavaju dva niza provrta, veći broj vijaka 1 veći broj matica.
the pharmaceutical agent of the above-mentioned [17], which is an agent for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; 
Farmaceutsko sredstvo prema zahtjevu 14, naznačeno time, da je to sredstvo za profilaksu ili liječenje hipogonadizma, poremećaja muškog klimakterija, nemoći, kaheksije ili osteoporoze.
The peptide according to claim 1 or 2, the nucleic acid or an expression vector according to claim 5, the cell according to claim 7, or the activated cytotoxic T lymphocyte according to claim 12 for use in the treatment of cancer, such as, for example, gastric, gastrointestinal, colorectal, pancreatic, lung or renal cancer. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 5, stanica u skladu sa zahtjevom 7 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 12 za uporabu u liječenju karcinoma, kao što su gastrični, gastrointestinalni, kolorektalni karcinomi te karcinomi gušterače, pluća ili bubrega.
The aerated mixture would then be misted out of nozzle 12 as forage 8 passes by the location of nozzle 12 to distribute the selected amount of mixture on forage. 
HR P20060161 T3 dok krupna stočna hrana 8 prolazi uz mlaznicu 12, da raspodijeli odabranu količinu mješavine na krupnu stočnu hranu.
As shown in Table 5, 42-O-(D-Fructosylcarbonyl)rapamycin prolonged survival of the graft at the 2.5 and 10 mg/kg/day dose level by 214 and 341% over the vehicle control. 
Kako je vidljivo iz Tablice 5, 42-0-(D- fruktozilkarbonil)rapamicin produljio je preživljenje transplantata u dozama od 2,5 mg/kg/dan i 10 mg/kg/dan i214i 341% više u usporedbi s kontrolom (nosačem).
The system according to claim 16, wherein the sealing member is deformable under the pressure of fluid injection. 
Sustav u skladu s patentnim zahtjevom 15, u kojemu se element za brtvljenje (8) deformira pod tlakom fluida koji se injektira.
the proximal end of the first fragment is located within a first repeat portion; 
(ili) proksimalni kraj prvog fragmenta se nalazi unutar prvog ponavljanog dijela;
Compound of formula (IV) polymorphic Form B: 
Spoj forumule (IV) polimorfnog oblika B:
A therapeutic antibody according to any one of claims 1 to 7 for use in the treatment of a disease characterised by elevated B-amyloid levels or B-amyloid deposits. 
Terapijsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 7, namijenjeno upotrebi u liječenju bolesti, naznačeno time što su za navedenu bolest karakteristične povišene razine P-amiloida ili naslage P-amiloida.
The antibody according to the disclosure may be used to treat cancer that is selected from the group consisting of breast cancer, prostate cancer, bone cancer, myeloma, colorectal cancer, leukaemia, lymphoma, skin cancer such as melanoma, oesophageal cancer, gastric cancer, astrocytic cancer, endometrial cancer, cervical cancer, bladder cancer, renal cancer, lung cancer, liver cancer, thyroid cancer, head and neck cancer, pancreatic cancer and ovarian cancer. 
Antitijelo za upotrebu prema patentnom zahtjevu 11 naznačeno time da je rak odabran iz skupine koja se sastoji od raka dojke, raka prostate, raka kostiju, kolorektalnog raka, leukemije, limfoma, raka kože, raka jednjaka, raka želuca, astrocitnog raka, raka endometrijuma, raka vrata materice, raka mokraćnog mjehura, raka bubrega, raka pluća, raka jetre, raka štitnjače, raka glave 1 vrata, raka gušterače i raka jajnika.
make each group in the same uplink resource set corresponding to one uplink resource index, and establish the corresponding relation between the uplink resource index and the at least one uplink resource in the same uplink resource set in terms of indication. 
BS prema zahtjevu 10, naznačena time da se nadalje sastoji od modula za mapiranje (703) koji je prilagođen za ostvarivanje odgovarajućeg odnosa između indeksa resursa za uzlaznu vezu i barem jednog resursa za uzlaznu vezu u smislu porijekla.
detecting the formation of the immunological complex; 
detektiranju nastajanja imunološkog kompleksa;
A method of therapeutically treating pre-eclampsia comprising: obtaining a conditioned medium by culturing in vitro an isolated placental mesenchymal stem cell population from the placenta of a pregnant woman not affected by pre-eclampsia in a basal serum-free liquid culture medium for at least three hours, 
Kondicionirani medij koji se može dobiti uzgojem mezenhimalnih matičnih stanica posteljice prikupljenih nakon poroda iz posteljice trudnica nepogođenih preeklampsijom u tekućem mediju kulture, kondicionirani medij sadrži barem stanicom lučene faktore interleukin-6 (IL-6), interleukin-10 (IL-10) i monocit kemoatraktant protein 1 (MCP-1).
Interferon-B-1a for use according to claim 5, wherein the titration package further comprises a dose-limiting titration device. 
Interferon-B-1a, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što titracijski paket dodatno sadrži titracijski uređaj s ograničenjem doze.
After stirring at room temperature for 15 minutes the reaction mixture was filtered through a fritted funnel and the precipitate washed with 1,4-dioxane. 
Nakon miješanja na sobnoj temperaturi tijekom 15 minuta, reakcijska smjesa se filtrira kroz 'fritted' lijevak i precipitat se ispere sa 1,4-dioksanom.
wherein R1 is as defined above, in the presence of a heterogeneous acid scavenger and of methyl triflate. 
Lo Ž Formula V gdje je R1 kako je prethodno definiran, u prisutnosti heterogenog hvatača kiselina.
The cell of claim 1, further comprising at least one second recombinant nucleic acid molecule encoding a peptide or polypeptide capable of eliciting an immune response in a mammal, wherein said cell is capable of secreting a polypeptide encoded by said at least one second recombinant nucleic acid molecule. 
Stanica mikobakterije (Mycobacterium), naznačena time što je oskudna ureazom, obuhvaća rekombinantnu molekulu nukleinske kiseline koja kodira fuzijski polipeptid koji obuhvaća (a) najmanje jednu domenu polipeptida, pri čemu ta polipetidna domena ima sposobnost izazvati imuni odgovor kod sisavca, i (b) domenu za bijeg iz fagolizosoma.
1 and 2), according to our preliminary experiments IL-18BP remains bound to the column at such a pH range. 
1 1 2), dolazi pri pH4, u skladu sa našim preliminarnim eksperimentima IL-18BP ostaje vezan na kolonu u navedenim rasponim pH vrijednosti.
According to the invention, the HCC is fibrolamellar variant of HCC, or mixed hepatocellular cholangiocarcinoma. In some embodiments the HCC is early stage HCC, non-metastatic HCC, primary HCC, advanced HCC, locally advanced HCC, metastatic HCC, HCC in remission, recurrent HCC, HCC in an adjuvant setting, or HCC in a neoadjuvant setting. 
Pripravak ili kombinacija za uporabu prema bilo kojem od zahtjeva 1-8, gdje je HCC karcinom stanica jetre, fibrolamelarna varijanta HCC-a, miješani hepatocelularni kolangiokarcinom, HCC ranog stadija, ne-metastatski HCC, primarni HCC, uznapredovali HCC, lokalno uznapredovali HCC, metastatski HCC, HCC u remisiji, ponavljajući HCC, HCC u adjuvansnom okruženju, ili HCC u ne-adjuvansnom okruženju.
The antibody or antigen-binding fragment thereof as claimed in claim 4, wherein the heavy chain is gamma 1 (Y1). 
Protutijelo ili njegov fragment koji se veže na antigen prema zahtjevu 4, naznačen(o) time, da jaki lanac je gama 1 (Y1).
According to what has been described, it is apparent that another advantage of the present invention is the ease with which the operating-threshold of the GFCI 1 can be set, i.e. by varying the value of the test-resistor 86. 
Prema onome što je opisano, očito je da je još jedna prednost opisanog izuma lakoća s kojom se može podešavati, promjenom vrijednosti otpornika 86.
The titled compound is prepared analogously to 4-bromomethyl-2-fluoro-1-methanesulfonyl-benzene by replacing 3,4-difluorobenzaldehyde with 4-fluorobenzaldehyde and by replacing methane sulfinic acid sodium salt with 2-propanesulfinic acid sodium salt. 
Naslovni spoj je proizveden analogno 4-brom-metil-2-fluor-1-metansulfonil-benzenu zamjenom 3,4-difluorbenzaldehida sa 4-fluorbenzaldehidom i zamjenom natrijeve soli metan-sulfinske kiseline s natrijevom soli 2-propan-sulfinske kiseline.
The pharmaceutical composition for use according to claim 10 or 11 in combination with anti-influenza therapy or in combination with a haemagglutinin containing influenza vaccine by contemporaneous or separate administration. 
Farmaceutski sastav prema zahtjevu 9 ili 10 za uporabu u skladu sa zahtjevom 9 ili 10, naznačen time, da se primjenjuje u kombinaciji sa cjepivom protiv gripe koje sadrži hemaglutinin, istodobnom ili odvojenom primjenom.
said outer layer comprising a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at pH 6 or above, and said inner layer comprising a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being a polycarboxylic acid polymer that is at least partially neutralised with at least 10% of the carboxylic acid groups in the form of carboxylate anions, 
pri čemu vanjski sloj sadrži smjesu prvog polimernog materijala koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima prag pH na pH 6 ili više, i pri čemu unutarnji sloj sadrži treći polimerni materijal koji je neionski polimer koji je topljiv u crijevnoj tekućini, ili gastrointestinalnoj tekućini, i najmanje jedan aditiv odabran iz puferskog sredstva i baze.
The composition or combination for use of claim 4, wherein the other agent inhibits a molecule selected from the group consisting of ABP1, ARHGAP4, HSPA8, LCP1, PACSIN2, RUNXITI, STMN1, and Tubulin, and TUBB4. 
Pripravak ili kombinacija za uporabu prema zahtjevu 4, gdje drugo sredstvo inhibira molekulu odabranu iz skupine koju čine ABP1, ARHGAP4, HSPA8, LCP1, PACSIN2, RUNXITI, STMNI, i Tubulin, te TUBB4.
The method of claim 1, wherein the step of providing comprises providing at least about 1000 L of a culture. 
Postupak prema Zahtjevu 1, gdje korak osiguravanja sadrži osiguravanje najmanje oko 1000 L kulture.
the cell is selected from the group consisting of a red blood cell (RBC) precursor cell and a hematopoietic stem cell; and/or 
(b) stanica je izabrana iz grupe koju čine prekursorska stanica crvenih krvnih stanica (RBC) i hematopoetska matična stanica; i/ili
The method of claim 1, wherein the antibody comprises a substitution in an Fc region. 
Protutijelo sukladno patentnom zahtjevu 6, naznačeno time, da protutijelo sadrži supstituciju u Fc regiji.
D is chosen from the series consisting of N(R2); 
D se bira iz skupine koju čine N(R");
a BCH decoder configured to BCH-decode the LDPC-decoded PLP data. 
BCH dekoder konfiguriran za BCH-dekodiranje LDPC-dekodiranih PLP podataka.
Preferred are the compounds of general formula (I) in which: 
Preferirani su spojevi opće formule (i) u kojima: n-3,